- Home
- PRQR vs ALDX Comparison
PRQR vs ALDX Comparison
Compare PRQR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | ALDX |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 293.0M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRQR | ALDX |
|---|---|---|
| Price | $2.33 | $4.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $8.14 | ★ $9.50 |
| AVG Volume (30 Days) | 540.5K | ★ 953.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,859,556.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $1.14 |
| 52 Week High | $3.46 | $7.20 |
Technical Indicators
Market Signals| Indicator | PRQR | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 39.04 |
| Support Level | $2.15 | $4.67 |
| Resistance Level | $2.42 | $5.04 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 79.70 | 3.42 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.